Literature DB >> 3135326

C3d,g is present in normal human epidermal basement membrane.

N Basset-Seguin1, M Dersookian, K Cehrs, K B Yancey.   

Abstract

mAb as well as polyclonal anti-human C3d antibodies were found to specifically bind to the epidermal basement membrane zone of normal human adult and neonatal skin in a linear continuous pattern on direct immunofluorescence microscopy. No such binding was found in dermal microvascular basement membranes. Studies of normal adult human skin using a rat mAb specific for C3g revealed the same pattern of epidermal basement membrane staining. Control polyclonal antibodies directed against C3, C3c, C5, IgG, IgA, or IgM showed no evidence of epidermal basement membrane binding or in situ deposits of immune complexes in samples of normal human skin that were all positive for C3d and C3g. Pre-adsorption of monoclonal or polyclonal anti-human C3d with purified human C3d completely blocked these reagents' epidermal basement membrane reactivity. Anti-human C3d epidermal basement membrane binding was not diminished by pre-treatment of substrate with antibodies directed against C3, C3c, C5, laminin, fibronectin, or type IV collagen as well as bullous pemphigoid, KF-1, or epidermolysis bullosa acquisita Ag. Direct immunofluorescence microscopy studies on 1 M NaCl split human skin showed that C3d and C3g were found in the base of the cleavage plane created within the lamina lucida. By immunoelectron microscopy, C3d was found along the base of the lamina densa and in the sublamina densa region of normal human epidermal basement membrane. Although anti-human C3d epidermal basement membrane binding was not altered by treatment of 6 micron skin sections with buffers of varying pH and ionic concentration, binding was abolished by treating dermal portions of salt split skin with 0.1 M dithiothreitol in 8 M urea. Studies of a patient with congenital C3 deficiency revealed that there was no binding of anti-human C3d or anti-human C3g to this subject's epidermal basement membrane. Moreover, treatment of this patient's skin with aged human serum containing C3d,g or purified human C3 did not restore epidermal basement membrane anti-human C3d binding. These studies demonstrate that C3d,g or a closely related C3 fragment is present in the epidermal basement membrane zone of normal human skin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135326

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Expression and localization of proteins of the complement system in human skin.

Authors:  N Dovezenski; R Billetta; I Gigli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers.

Authors:  H Dauchel; P Joly; A Delpech; E Thomine; F Sauger; X Le Loet; P Lauret; F Tron; M Fontaine; J Ripoche
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

3.  Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice.

Authors:  Z Lazarova; C Yee; T Darling; R A Briggaman; K B Yancey
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

4.  Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in rats.

Authors:  Y Suwa; I Kudo; A Imaizumi; M Okada; T Kamimura; Y Suzuki; H W Chang; S Hara; K Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

5.  Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance.

Authors:  C Hammerberg; S K Katiyar; M C Carroll; K D Cooper
Journal:  J Exp Med       Date:  1998-04-06       Impact factor: 14.307

6.  Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?

Authors:  K R van Straalen; K Dudink; P Aarts; H H van der Zee; T P P van den Bosch; J Giang; E P Prens; J Damman
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.